Positron Corporation Secures Agreement for Three NeuSight PET-CT 64 Slice Scanners
Positron (OTC: POSC) has secured an agreement for three NeuSight PET-CT 64-slice scanners under its Prime Rental Program with a leading cardiovascular practice. The NeuSight PET-CT features a 72 cm gantry and high-sensitivity acquisition technology, offering reduced radiation exposure and superior imaging capabilities.
The system boasts the smallest footprint among PET-CT systems and excels in both cardiology and oncology studies. Key features include advanced data acquisition technology for faster and more precise scans, supporting various molecular imaging applications including heart, tumor, and brain studies.
Positron (OTC: POSC) ha ottenuto un accordo per tre scanner NeuSight PET-CT a 64 strati nell'ambito del suo Programma di Noleggio Prime con una rinomata pratica cardiovascolare. Il NeuSight PET-CT presenta un gantry di 72 cm e una tecnologia di acquisizione ad alta sensibilità, offrendo una riduzione dell'esposizione alle radiazioni e capacità di imaging superiori.
Il sistema vanta la più piccola impronta tra i sistemi PET-CT ed eccelle negli studi di cardiologia e oncologia. Le caratteristiche principali includono una tecnologia avanzata di acquisizione dei dati per scansioni più rapide e precise, supportando diverse applicazioni di imaging molecolare, tra cui studi sul cuore, tumori e cervello.
Positron (OTC: POSC) ha asegurado un acuerdo para tres escáneres NeuSight PET-CT de 64 cortes bajo su Programa de Alquiler Prime con una destacada práctica cardiovascular. El NeuSight PET-CT cuenta con un gantry de 72 cm y una tecnología de adquisición de alta sensibilidad, ofreciendo una reducción en la exposición a la radiación y capacidades de imagen superiores.
El sistema tiene la huella más pequeña entre los sistemas PET-CT y sobresale en estudios de cardiología y oncología. Las características clave incluyen tecnología avanzada de adquisición de datos para escaneos más rápidos y precisos, apoyando diversas aplicaciones de imagen molecular, incluidos estudios del corazón, tumores y cerebro.
포지트론 (OTC: POSC)은 주요 심혈관 클리닉과 함께 Prime Rental Program에 따라 64슬라이스 NeuSight PET-CT 스캐너 3대에 대한 계약을 체결했습니다. NeuSight PET-CT는 72cm의 gantry와 고감도 획득 기술을 갖추고 있어 방사선 노출을 줄이고 우수한 이미징 능력을 제공합니다.
이 시스템은 PET-CT 시스템 중 가장 작은 면적을 자랑하며, 심장학 및 종양학 연구에서 뛰어난 성능을 발휘합니다. 주요 특징으로는 더 빠르고 정확한 스캔을 지원하는 고급 데이터 획득 기술이 포함되어 있으며, 심장, 종양 및 뇌 연구를 포함한 다양한 분자 이미징 응용 프로그램을 지원합니다.
Positron (OTC: POSC) a sécurisé un accord pour trois scanners NeuSight PET-CT à 64 coupes dans le cadre de son Programme de Location Prime avec une pratique cardiovasculaire de premier plan. Le NeuSight PET-CT dispose d'un gantry de 72 cm et d'une technologie d'acquisition à haute sensibilité, offrant une réduction de l'exposition aux radiations et des capacités d'imagerie supérieures.
Le système se distingue par son empreinte la plus petite parmi les systèmes PET-CT et excelle dans les études de cardiologie et d'oncologie. Les caractéristiques clés incluent une technologie avancée d'acquisition de données pour des scans plus rapides et plus précis, prenant en charge diverses applications d'imagerie moléculaire, y compris des études sur le cœur, les tumeurs et le cerveau.
Positron (OTC: POSC) hat einen Vertrag über drei NeuSight PET-CT 64-Schicht-Scanner im Rahmen seines Prime Rental Program mit einer führenden kardiovaskulären Praxis gesichert. Der NeuSight PET-CT verfügt über einen 72 cm großen Gantry und eine hochsensible Erfassungstechnologie, die eine reduzierte Strahlenexposition und überlegene Bildgebungsfähigkeiten bietet.
Das System hat die kleinste Stellfläche unter den PET-CT-Systemen und glänzt sowohl in der Kardiologie als auch in der Onkologie. Zu den wichtigsten Merkmalen gehören fortschrittliche Datenakquisitionstechnologie für schnellere und präzisere Scans, die verschiedene molekulare Bildgebungsanwendungen unterstützen, einschließlich Studien zu Herz, Tumoren und Gehirn.
- Secured agreement for three new PET-CT scanner installations
- Offers Prime Rental Program making advanced imaging more accessible
- System features smallest footprint in PET-CT market
- Supports multiple revenue streams (cardiology and oncology applications)
- Financial terms of the agreement not disclosed
- Revenue impact and timeline not specified
Niagara Falls, NY, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Positron Corporation (OTC: POSC), a leading molecular imaging medical device company specializing in PET and PET-CT imaging systems and clinical support services, is pleased to announce it has entered an agreement for three NeuSight PET-CT 64-slice scanners under its Prime Rental Program, to a leading cardiovascular diagnostic, management, and treatment practice.
Positron’s commitment to collaborating with such leaders in cardiovascular health plays an important role in the advancement of nuclear cardiology and reinforces its objective to drive the adoption of cardiac PET-CT imaging. Positron is committed to advancing nuclear cardiology by delivering cutting-edge imaging technology that enhances diagnostic values, improves patient outcomes and optimizes practice efficiencies. As the industry transitions to cardiac PET-CT imaging, Positron’s innovative and cost-effective solutions make advanced imaging more accessible to all practices, ultimately shaping the future of cardiovascular care.
The NeuSight PET-CT is designed to transform cardiac PET imaging by combining exceptional performance, advanced technology, and unmatched value. Renowned for its top-tier performance and international success, the NeuSight PET-CT stands out with its patient-centered design, featuring a spacious 72 cm gantry for enhanced comfort and high-sensitivity acquisition technology that minimizes radiation exposure for both patients and technicians. With the smallest footprint and lightest weight among PET-CT systems, it offers superior imaging capabilities while optimizing space utilization, making it an ideal solution for modern healthcare facilities.
As a cost-effective and innovative system, the NeuSight PET-CT excels in both cardiology and oncology clinical studies. Its advanced data acquisition and identification technology enable faster and more precise scans, improving diagnostic accuracy. Offering both anatomic and functional imaging, the NeuSight PET-CT supports a wide range of molecular imaging applications, including heart, tumor, and brain studies, showcasing its versatility and commitment to advancing medical diagnostics.
Adel Abdullah, President of Positron, stated, "We are proud to support innovators in nuclear cardiology and help our customers uphold the highest standards of cardiac care. Our comprehensive rental program ensures accessibility, while our expert team provides the training and support needed for continued success." Mr. Abdullah added, "Positron delivers the best in cardiac PET and PET-CT imaging, empowering physicians with advanced technology, including data quantification and CFR applications. Our solutions combine cutting-edge performance, comprehensive support services with cost-effectiveness, which provides the ideal choice for nuclear imaging practices."
ABOUT POSITRON CORPORATION
Positron Corporation is a medical technology company that co-develops, manufactures, and sells state-of-the-art PET and PET-CT imaging systems and clinical services to nuclear medicine healthcare providers throughout North America.
Positron specializes in the field of cardiac Positron Emission Tomography (PET) imaging, the gold standard in cardiac diagnostics. Positron’s innovative PET/PET-CT technologies, clinical services and practice solutions enables healthcare providers to accurately diagnose coronary artery disease and improve patient outcomes while practicing cost effective medicine.
Positron's Attrius® PET and NeuSight PET-CT imaging systems and distinct market position are substantial advantages unique to Positron that will facilitate the adoption of cardiac PET and the growth of the nuclear imaging market. Positron will soon offer a state-of-the-art PET-CT 4D molecular imaging device in the Affinity PET-CT 4D 64-Slice. Positron’s PET-CT(s) will enable nuclear cardiologists to utilize the full capabilities of molecular imaging and nuclear medicine. Positron’s PET-CT systems will also enable the Company to fully service and meet the demands of the vast oncology imaging segment of nuclear medicine.
Positron is committed to expanding the cardiac and oncology PET modality by delivering the best technology and value to imaging specialists and will continue to advance its technology through its co-developer, supplier, and R&D venture with Shenyang Intelligent Neuclear Technology Co. a subsidiary of Neusoft Medical Systems.
Please visit the Company’s website at: www.positron.com
FORWARD-LOOKING STATEMENTS
This press release contains statements which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Positron Corporation, and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results even if new information becomes available in the future.
FOR FURTHER INFORMATION, please visit the company’s website at www.positron.com, or contact: investor@positron.com
FAQ
What is the significance of Positron's (POSC) new scanner agreement?
What are the key features of POSC's NeuSight PET-CT scanner?
How does the NeuSight PET-CT scanner benefit medical practices?
What applications does POSC's NeuSight PET-CT scanner support?
